Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
J Headache Pain. 2022 Feb 17;23(1):26. doi: 10.1186/s10194-022-01394-z.
5-Hydroxytryptamine (5-HT) receptors 1B, 1D and 1F have key roles in migraine pharmacotherapy. Selective agonists targeting these receptors, such as triptans and ditans, are effective in aborting acute migraine attacks and inhibit the in vivo release of calcitonin gene-related peptide (CGRP) in human and animal models. The study aimed to examine the localization, genetic expression and functional aspects of 5- HT receptors in the trigeminal system in order to further understand the molecular sites of action of triptans (5-HT) and ditans (5-HT).
Utilizing immunohistochemistry, the localization of 5-HT and of 5-HT receptors was examined in rat trigeminal ganglion (TG) and combined with quantitative polymerase chain reaction to quantify the level of expression for 5-HT receptors in the TG. The functional role of these receptors was examined ex vivo with a capsaicin/potassium induced 5-HT and CGRP release.
5-HT immunoreactivity (ir) was observed in a minority of CGRP negative C-fibres, most neuron somas and faintly in A-fibres and Schwann cell neurolemma. 5-HT receptors were expressed in the TG, while the 5-HT receptor displayed a weak ir. The 5-HT receptor co-localized with receptor activity-modifying protein 1 (RAMP1) in Aδ-fibres in the TG, while 5-HT-ir was weakly expressed and 5-HT-ir was not detected in these fibres. None of the 5-HT receptors co-localized with CGRP-ir in C-fibres. 5-HT receptor mRNA was the most prominently expressed, followed by the 5-HT receptor and lastly the 5-HT receptor. The 5-HT and 5-HT receptor antagonist, GR127935, could reverse the inhibitory effect of Lasmiditan (a selective 5-HT receptor agonist) on CGRP release in the soma-rich TG but not in soma-poor TG or dura mater. 5-HT release in the soma-rich TG, and 5-HT content in the baseline samples, negatively correlated with CGRP levels, showing for the first time a physiological role for 5-HT induced inhibition.
This study reveals the presence of a subgroup of C-fibres that store 5-HT. The data shows high expression of 5-HT receptors and suggests that the 5-HT receptor is a relatively unlikely target in the rat TG. Furthermore, Lasmiditan works as a partial agonist on 5-HT receptors in clinically relevant dose regiments.
5-羟色胺(5-HT)受体 1B、1D 和 1F 在偏头痛的药物治疗中起着关键作用。针对这些受体的选择性激动剂,如曲坦类和 ditans,在终止急性偏头痛发作方面非常有效,并且可以抑制在体内释放降钙素基因相关肽(CGRP)在人和动物模型中。本研究旨在检查 5- HT 受体在三叉神经系统中的定位、遗传表达和功能方面,以进一步了解曲坦类(5-HT)和 ditans(5-HT)的分子作用部位。
利用免疫组织化学方法,检查大鼠三叉神经节(TG)中 5-HT 和 5-HT 受体的定位,并结合定量聚合酶链反应,定量测定 TG 中 5-HT 受体的表达水平。这些受体的功能作用通过辣椒素/钾诱导的 5-HT 和 CGRP 释放进行离体检查。
在少数 CGRP 阴性 C 纤维中观察到 5-HT 免疫反应性(ir),大多数神经元体和 A 纤维和施万细胞神经膜中也有微弱的 ir。5-HT 受体在 TG 中表达,而 5-HT 受体显示出微弱的 ir。5-HT 受体与受体活性修饰蛋白 1(RAMP1)在 TG 中的 Aδ纤维中共同定位,而 5-HT-ir 表达较弱,并且在这些纤维中未检测到 5-HT-ir。5-HT 受体在 C 纤维中均未与 CGRP-ir 共定位。5-HT 受体 mRNA 的表达最为显著,其次是 5-HT 受体,最后是 5-HT 受体。5-HT 和 5-HT 受体拮抗剂 GR127935 可逆转 Lasmiditan(一种选择性 5-HT 受体激动剂)对 soma-rich TG 中 CGRP 释放的抑制作用,但对 soma-poor TG 或硬脑膜无影响。soma-rich TG 中的 5-HT 释放和基线样本中的 5-HT 含量与 CGRP 水平呈负相关,首次显示 5-HT 诱导的抑制具有生理作用。
本研究揭示了存在一组储存 5-HT 的 C 纤维亚群。数据显示 5-HT 受体的高表达表明 5-HT 受体在大鼠 TG 中不太可能成为相对的靶点。此外,在临床相关剂量范围内,Lasmiditan 作为 5-HT 受体的部分激动剂起作用。